Controlling lipid levels with fewer side effects possible with new drug

Researchers have developed a new compound, ZTA-261, that binds to thyroid hormone receptor beta (THR ). THR plays an important role in the regulation of lipid metabolism, which affects lipid levels in the blood. Mice administered the drug showed decreased lipid levels in the liver and blood, with fewer side effects in the liver, heart, and bones compared to existing compounds. The findings suggest an effective treatment for lipid disorders such as dyslipidemia.